The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...
3h
Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback